- Home
- CTO vs ORIC Comparison
CTO vs ORIC Comparison
Compare CTO & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | ORIC |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 586.6M | 783.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTO | ORIC |
|---|---|---|
| Price | $18.45 | $12.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $22.00 | $19.73 |
| AVG Volume (30 Days) | 279.4K | ★ 1.8M |
| Earning Date | 02-19-2026 | 02-17-2026 |
| Dividend Yield | ★ 8.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $146,948,000.00 | N/A |
| Revenue This Year | $20.87 | N/A |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.84 | N/A |
| 52 Week Low | $15.07 | $3.90 |
| 52 Week High | $20.88 | $14.93 |
Technical Indicators
Market Signals| Indicator | CTO | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 57.27 | 75.74 |
| Support Level | $18.00 | $7.84 |
| Resistance Level | $18.71 | $11.78 |
| Average True Range (ATR) | 0.31 | 0.65 |
| MACD | -0.02 | 0.54 |
| Stochastic Oscillator | 63.51 | 98.08 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.